PrognomiQ Inc. Company Profile

Background

Overview

PrognomiQ Inc. is a privately held biotechnology company founded in 2020, headquartered in San Mateo, California. The company specializes in developing innovative multi-omics platforms aimed at the early detection and treatment of complex diseases, particularly cancer. By integrating proteomic, genomic, and metabolomic data, PrognomiQ seeks to transform healthcare through advanced diagnostic solutions.

Mission and Vision

PrognomiQ's mission is to revolutionize the detection and early treatment of cancer and other complex diseases by harnessing the power of multi-omics data. The company's vision is to provide high-quality, multi-omics data that offers unparalleled biological insights, facilitating earlier disease detection and more effective treatment strategies.

Industry Significance

Operating within the biotechnology sector, PrognomiQ addresses a critical need for advanced diagnostic tools capable of early disease detection. By leveraging multi-omics data, the company aims to enhance the precision and efficacy of medical diagnostics, thereby improving patient outcomes and advancing personalized medicine.

Key Strategic Focus

Core Objectives

PrognomiQ is dedicated to developing transformative test products that enable early disease detection and treatment. The company's strategic focus includes:

• High-Quality Multi-Omics Data Generation: Producing extensive proteomic data complemented by genomic and metabolomic information to uncover complex disease mechanisms.

• Innovative Diagnostic Solutions: Creating next-generation diagnostic tools that facilitate early detection and monitoring of diseases.

Areas of Specialization

The company specializes in:

• Proteomics: Generating comprehensive proteomic data to understand disease mechanisms.

• Genomics and Metabolomics: Integrating genomic and metabolomic data to enhance diagnostic accuracy.

Key Technologies Utilized

PrognomiQ employs advanced technologies, including:

• Next-Generation Sequencing (NGS): For comprehensive genomic analysis.

• Mass Spectrometry: To perform detailed proteomic and metabolomic profiling.

Primary Markets Targeted

The company's primary focus is on the oncology market, aiming to develop diagnostic solutions for early cancer detection and monitoring.

Financials and Funding

Funding History

Since its inception, PrognomiQ has secured substantial funding through multiple financing rounds:

• Series D Financing (November 2024): Raised $34 million, led by Seer, Inc., with participation from a new strategic investor in the diagnostics segment and existing investors, including Catalio Capital Management, aMoon, Invus, and Bruker. This round brought the total funding to over $135 million.

• Series C Financing (March 2022): Secured $46 million, led by Bruker Corporation, with participation from new investors like Catalio Capital Management and existing investors such as aMoon, Fidelity Management and Research Company LLC, T. Rowe Price Associates, Inc., Invus, Maverick Ventures, Emerson Collective, and Wing VC.

Utilization of Capital

The funds raised are primarily allocated towards:

• Advancing Diagnostic Development: Enhancing the development of early detection tests for lung cancer and other complex diseases.

• Expanding Research Capabilities: Investing in research and development to refine multi-omics platforms and diagnostic tools.

Pipeline Development

Key Pipeline Candidates

PrognomiQ is focusing on developing diagnostic tests for early disease detection, with a particular emphasis on:

• Lung Cancer Detection: Developing a lab-developed test (LDT) for early lung cancer detection, with plans to transition to an In Vitro Diagnostics (IVD) test.

Stages of Development

The lung cancer detection test is in the advanced stages of development, with ongoing efforts to validate and refine the diagnostic platform.

Target Conditions

The primary target condition is lung cancer, with potential applications in other complex diseases as the platform evolves.

Anticipated Milestones

PrognomiQ aims to achieve the following milestones:

• Clinical Validation: Conducting comprehensive clinical studies to validate the diagnostic accuracy of the lung cancer test.

• Regulatory Approval: Seeking regulatory approvals for the transition from LDT to IVD status.

Technological Platform and Innovation

Proprietary Technologies

PrognomiQ's proprietary technologies include:

• Multi-Omics Integration: Combining proteomic, genomic, and metabolomic data to provide a holistic view of disease mechanisms.

• Advanced Data Analytics: Utilizing sophisticated algorithms and machine learning techniques to interpret complex multi-omics datasets.

Significant Scientific Methods

The company employs:

• High-Throughput Mass Spectrometry: For detailed proteomic and metabolomic analysis.

• Comprehensive Genomic Sequencing: To capture a wide range of genetic information.

AI-Driven Capabilities

PrognomiQ integrates artificial intelligence to:

• Data Interpretation: Enhance the analysis of multi-omics data for more accurate diagnostics.

• Predictive Modeling: Develop predictive models for disease progression and treatment response.

Leadership Team

Executive Profiles

• Philip Ma, PhD: Chief Executive Officer and Founder. Previously, he was Chief Business Officer, President, and Founder of Seer. He also served as Vice-President for Digital Health Technologies and Data Sciences at Biogen and was a Senior Partner at McKinsey & Company.